Targeted treatments for multiple myeloma: specific role of carfilzomib

References

• American Cancer SocietyMultiple Myeloma8102014 Available from: http://www.cancer.org/cancer/multiplemyeloma/
   Google Scholar
• National Comprehensive Cancer NetworkMultiple Myeloma (Version 1.2015)8102014 Available from: http://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf
   Google Scholar
• van de DonkNWTreatment of relapsed and refractory multiple myeloma in the era of novel agentsCancer Treat Rev201137426628320863623
   PubMed Web of Science ®Google Scholar
• OrlowskiMWilkSCatalytic activities of the 20 S proteasome, a multicatalytic proteinase complexArch Biochem Biophys2000383111611097171
   PubMed Web of Science ®Google Scholar
• RockKLInhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I moleculesCell19947857617718087844
   PubMed Web of Science ®Google Scholar
• KuhnDJPotent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myelomaBlood200711093281329017591945
   PubMed Web of Science ®Google Scholar
• MengLEpoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activityProc Natl Acad Sci U S A19999618104031040810468620
   PubMed Web of Science ®Google Scholar
• ParlatiFLSAujayMCarfilzomib: a selective inhibitor of the chymotrypsin-like activity of the constitutive proteasome and immunoproteasome has anti-tumor activity on multiple myeloma, lymphoma, and leukemia cells with minimal effects on normal cellsHaematologica94Suppl 2
   Google Scholar
• DemoSDAntitumor activity of PR-171, a novel irreversible inhibitor of the proteasomeCancer Res200767136383639117616698
   PubMed Web of Science ®Google Scholar
• SuzukiEBortezomib-Resistant Cell Lines Have Increased Proteasome Levels but Remain Sensitive to CarfilzomibASH Annual Meeting Abstracts2009114222852
   Google Scholar
• IvancsitsDThe Proteasome Inhibitor PR-171 Inhibits Cell Growth, Induces Apoptosis, and Overcomes De Novo and Acquired Drug Resistance in Human Multiple Myeloma CellsASH Annual Meeting Abstracts2005106111575
   Google Scholar
• AlsinaMA phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphomaClin Cancer Res201218174830484022761464
   PubMed Web of Science ®Google Scholar
• O’ConnorOAA phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignanciesClin Cancer Res200915227085709119903785
   PubMed Web of Science ®Google Scholar
• Kyprolis (carfilzomib) for Injection Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202714lbl.pdf
   Google Scholar
• SiegelDSA phase 2 study of single-agent carfilzomib (PX-171–003-A1) in patients with relapsed and refractory multiple myeloma201212028172825
   Google Scholar
• PapadopoulosKPPhase I Study of 30-Minute Infusion of Carfilzomib As Single Agent or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and/or Refractory Multiple MyelomaJ Clin Oncol2014
   Google Scholar
• VijRAn open-label, single-arm, phase 2 (PX-171–004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myelomaBlood2012119245661567022555973
   PubMed Web of Science ®Google Scholar
• Amgen Announces Top-Line Results From Phase 3 Focus Trial Of Kyprolis® In Patients With Relapsed And Advanced Refractory Multiple Myeloma8122014 Available from: http://www.amgen.com
   Google Scholar
• KleinLA Phase 1, Dose-Escalation Study (CHAMPION-1) Investigating Weekly Carfilzomib In Combination With Dexamethasone For Patients With Relapsed Or Refractory Multiple Myeloma201312219341934
   Google Scholar
• LendvaiNA phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myelomaBlood2014124689990624963043
   PubMed Web of Science ®Google Scholar
• WangMPhase 2 dose-expansion study (PX-171–006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myelomaBlood2013122183122312824014245
   PubMed Web of Science ®Google Scholar
• NiesvizkyRPhase Ib dose-escalation study (PX-171–006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myelomaClin Cancer Res20131982248225623447001
   PubMed Web of Science ®Google Scholar
• StadtmauerEAPhase I/II Dose Expansion Of a Multi-Center Trial Of Carfilzomib and Pomalidomide With Dexamethasone (Car-Pom-d) In Patients With Relapsed/Refractory Multiple Myeloma2013122690690
   Google Scholar
• FengLPhase 1 Study Of The Novel Kinesin Spindle Protein Inhibitor ARRY-520 + Carfilzomib (Car) In Patients With Relapsed and/Or Refractory Multiple Myeloma (RRMM)201312219821982
   Google Scholar
• AmgenAmgen Announces Phase 3 ASPIRE Trial of Kyprolis In Patients With Relapsed Multiple Myeloma Met Primary Endpoint842014 Available from: http://www.amgen.com
   Google Scholar
• JakubowiakAJTreatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-upASCO Meeting Abstracts20133115_suppl8543
   Google Scholar
• AllanJNCar-Bird [Carfilzomib, Clarithromycin(Biaxin(R)), Lenalidomide/(Revlimid(R)), Dexamethasone) For Newly-Diagnosed Multiple Myeloma201312232163216
   Google Scholar
• ZingoneAPhase II Clinical and Correlative Study Of Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Extended Dosing (CRD-R) Induces High Rates Of MRD Negativity In Newly Diagnosed Multiple Myeloma (MM) Patients2013122538538
   Google Scholar
• Asselberg-HackerEDose Escalation Phase 2 Trial Of Carfilzomib Combined With Thalidomide and Low-Dose Dexamethason In Newly Diagnosed, Transplant Eligible Patients With Multiple MyelomaA Trial Of The European Myeloma Network2013122688688
   Google Scholar
• ReederCBA Phase I/II Trial Of Cyclophosphamide, Carfilzomib, Thalidomide and Dexamethasone (CYCLONE) In Patients With Newly Diagnosed Multiple Myeloma: Final Results Of MTD Expansion Cohort201312231793179
   Google Scholar
• MailankodySClinical and Correlative Pilot Study Of Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Extended Dosing (CRd – R) In High Risk Smoldering Multiple Myeloma Patients201312219391939
   Google Scholar
• BladeJRenal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institutionArch Intern Med199815817188918939759684
   PubMedGoogle Scholar
• BadrosAZCarfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safetyLeukemia20132781707171423364621
   PubMed Web of Science ®Google Scholar
• WisloffFHas the incidence of multiple myeloma in old age been underestimated? The myeloma project of health region I in NorwayI Eur J Haematol1991475333337
   Web of Science ®Google Scholar
• JagannathSAn open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myelomaClin Lymphoma Myeloma Leuk201212531031823040437
   PubMed Web of Science ®Google Scholar
• BringhenSCarfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 studyBlood20141241636924855212
   PubMed Web of Science ®Google Scholar
• TouzeauCEffect of CMP, carfilzomib (CFZ) plus melphalan-prednisone (MP), on response rates in elderly patients (pts) with newly diagnosed multiple myeloma (NDMM): Results of a phase (Ph) I/II trialASCO Meeting Abstracts20133115_suppl8513
   Google Scholar
• MunshiNCConsensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2Blood2011117184696470021292777
   PubMed Web of Science ®Google Scholar
• SawyerJRThe prognostic significance of cytogenetics and molecular profiling in multiple myelomaCancer Genet2011204131221356186
   PubMed Web of Science ®Google Scholar
• MorganGJWalkerBADaviesFEThe genetic architecture of multiple myelomaNat Rev Cancer201212533534822495321
   PubMed Web of Science ®Google Scholar
• KyleRARajkumarSVCriteria for diagnosis, staging, risk stratification and response assessment of multiple myelomaLeukemia20092313918971951
   PubMed Web of Science ®Google Scholar
• NebenKAdministration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17pBlood2012119494094822160383
   PubMed Web of Science ®Google Scholar
• Avet-LoiseauHBortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p)J Clin Oncol201028304630463420644101
   PubMed Web of Science ®Google Scholar
• JagannathSBortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trialsLeukemia200721115115717096017
   PubMed Web of Science ®Google Scholar
• JakubowiakAJTreatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171–003-A1 studyLeukemia201327122351235623670297
   PubMed Web of Science ®Google Scholar
• SiegelDIntegrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studiesHaematologica201398111753176123935022
   PubMed Web of Science ®Google Scholar
• Onyx Pharmaceuticals. ClinicalTrials.govPhase 3 Study with Carfilzomib and Dexamethasone versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients (ENDEAVOR) Available from: http://clinicaltrials.gov/show/NCT01568866. NLM identifier: NCT01568866Accessed: August 10, 2014
   Google Scholar
• Onyx Pharmaceuticals. ClinicalTrials.govPhase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma (CLARION) Available from: http://clinicaltrials.gov/show/NCT01818752. NLM identifier: NCT01818752Accessed: August 10, 2014
   Google Scholar
• Columbia University. ClinicalTrials.govCarfilzomib With Benda-mustine and Dexamethasone in Multiple Myeloma Available from: http://clinicaltrials.gov/ct2/show/NCT02002598. NLM identifier: NCT02002598Accessed: August 10, 2014
   Google Scholar
• Medical University of South Carolina. ClinicalTrials.govCarfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation Available from: http://clinicaltrials.gov/ct2/show/NCT01690143. NLM identifier: NCT01690143Accessed: August 10, 2014
   Google Scholar
• University of Chicago. ClinicalTrials.govCarfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma Available from: http://clinicaltrials.gov/ct2/show/NCT01816971. NLM identifier: NCT01816971Accessed: August 10, 2014
   Google Scholar
• National Cancer Institute. ClinicalTrials.govCarfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma Available from: http://clinicaltrials.gov/show/NCT01572480. NLM identifier: NCT01572480Accessed: August 10, 2014
   Google Scholar
• Onyx Pharmaceuticals. ClinicalTrials.govStudy of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib Available from: http://clinicaltrials.gov/ct2/show/NCT01775553. NLM identifier: NCT01775553Accessed: August 10, 2014
   Google Scholar
• Pharmacyclics. ClinicalTrials.govStudy of the Bruton’s Tyrosine Kinase Inhibitor in Combination With Carfilzomib (Kyprolis™), in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma Available from: http://clinicaltrials.gov/ct2/show/NCT01962792. NLM identifier: NCT01962792Accessed: August 10, 2014
   Google Scholar
• M.D. Anderson Cancer Center. ClinicalTrials.govArry-520 + Carfilzomib for Multiple Myeloma (MM) Available from: http://clinicaltrials.gov/ct2/show/NCT01372540. NLM identifier: NCT01372540Accessed: August 10, 2014
   Google Scholar
• Southwest Oncology Group. ClinicalTrials.govS1304, Testing Two Doses of Carfilzomib With Dexamethasone for Relapsed or Refractory Myeloma Available from: http://clinicaltrials.gov/ct2/show/NCT01903811. NLM identifier: NCT01903811Accessed: August 10, 2014
   Google Scholar
• Emory University. ClinicalTrials.govA Phase I Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed and/or Refractory Multiple Myeloma Available from: http://clinicaltrials.gov/ct2/show/NCT01549431. NLM identifier: NCT01549431Accessed: August 10, 2014
   Google Scholar
• University of Chicago. ClinicalTrials.govCarfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Available from: http://clinicaltrials.gov/ct2/show/NCT01665794. NLM identifier: NCT01665794Accessed: August 10, 2014
   Google Scholar
• Hackensack University Medical Center. ClinicalTrials.govA Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (QUAD) Available from: http://clinicaltrials.gov/ct2/show/NCT01297764. NLM identifier: NCT01297764Accessed: August 10, 2014
   Google Scholar
• Washington University School of Medicine. ClinicalTrials.govCarfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Available from: http://clinicaltrials.gov/ct2/show/NCT01246063. NLM identifier: NCT01246063Accessed: August 10, 2014
   Google Scholar
• Oncotherapeutics. ClinicalTrials.govSafety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma Available from: http://clinicaltrials.gov/ct2/show/NCT01792102. NLM identifier: NCT01792102Accessed: August 10, 2014
   Google Scholar
• M.D. Anderson Cancer Center. ClinicalTrials.govCarfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma Available from: http://clinicaltrials.gov/show/NCT02114502. NLM identifier: NCT02114502Accessed: August 10, 2014
   Google Scholar